ERIS Lifesciences Adjusts Technical Outlook Amid Strong Profit Growth and Valuation Challenges
ERIS Lifesciences has recently experienced a change in its evaluation, reflecting a shift in market sentiment. The company showcases strong management efficiency with a return on capital employed of 17.80% and a low Debt to EBITDA ratio. Despite a significant profit increase, long-term growth challenges persist.
ERIS Lifesciences, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting a shift in its technical outlook. The stock's technical trend has transitioned from bullish to mildly bullish, indicating a nuanced change in market sentiment.Key financial metrics reveal a strong management efficiency, highlighted by a return on capital employed (ROCE) of 17.80%. The company also demonstrates a solid ability to service its debt, evidenced by a low Debt to EBITDA ratio of 1.15 times. In the latest quarter, ERIS Lifesciences reported a significant increase in profit after tax (PAT), reaching Rs 117.99 crore, which marks a growth of 41.6%.
Despite these positive indicators, the company faces challenges with long-term growth, as its operating profit has expanded at an annual rate of 18.17% over the past five years. The stock is currently trading at a discount compared to its peers' average historical valuations, with a PEG ratio of 38.2, suggesting a complex valuation landscape.
For those interested in tracking the latest developments, including the stock's score and financial trend performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
